Payment overview · 2025
General Payments
$963.98
50 reported records · 15 companies
Healthcare provider profile · identity verified
Ritu Suri, MD
Allopathic & Osteopathic Physicians|Family Medicine|Geriatric Medicine · ENGLEWOOD, NJ · NPI 1972696409
Verified facts
What the public records show
CMS Open Payments records show Ritu Suri, MD received $963.98 in general payments during 2025 across 50 reported records.
Lilly USA, LLC accounted for 20.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance, Mounjaro, Rexulti, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Lokelma by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Entresto by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Abilify Maintena by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rexulti by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Lantus by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $194.04 | 20.1% | 11 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $158.25 | 16.4% | 7 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $129.30 | 13.4% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $104.58 | 10.8% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $99.04 | 10.3% | 6 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $53.48 | 5.5% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $37.65 | 3.9% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.91 | 3.6% | 2 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $34.38 | 3.6% | 2 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $27.36 | 2.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.69 | 2.1% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $19.94 | 2.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.60 | 1.9% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $17.63 | 1.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.13 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $963.98 | 50 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $158.25 | 7 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $129.30 | 6 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $120.51 | 7 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $104.58 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $73.67 | 4 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $53.48 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $49.44 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $37.65 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $34.91 | 2 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $27.36 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.69 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $19.94 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $18.77 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $17.63 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.13 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 98 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 165 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
98 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
40 | 15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
165 | 26 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
165 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
47 | 13 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
65 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1235 | 226 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1012 | 164 |
| Eliquis | Apixaban | 709 | 94 |
| Amlodipine Besylate | Amlodipine Besylate | 696 | 161 |
| Metoprolol Succinate | Metoprolol Succinate | 565 | 112 |
| Furosemide | Furosemide | 540 | 106 |
| Losartan Potassium | Losartan Potassium | 536 | 113 |
| Pantoprazole Sodium | Pantoprazole Sodium | 464 | 89 |
| Divalproex Sodium | Divalproex Sodium | 448 | 87 |
| Gabapentin | Gabapentin | 438 | 72 |
| Escitalopram Oxalate | Escitalopram Oxalate | 420 | 64 |
| Metoprolol Tartrate | Metoprolol Tartrate | 418 | 75 |
| Potassium Chloride | Potassium Chloride | 410 | 63 |
| Sertraline Hcl | Sertraline Hcl | 390 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 381 | 72 |
| Omeprazole | Omeprazole | 378 | 70 |
| Mirtazapine | Mirtazapine | 373 | 75 |
| Famotidine | Famotidine | 303 | 58 |
| Trazodone Hcl | Trazodone Hcl | 301 | 58 |
| Metformin Hcl | Metformin Hcl | 299 | 67 |
| Lisinopril | Lisinopril | 292 | 51 |
| Simvastatin | Simvastatin | 268 | 48 |
| Donepezil Hcl | Donepezil Hcl | 258 | 50 |
| Clopidogrel | Clopidogrel Bisulfate | 241 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 232 | 62 |
| Hydralazine Hcl | Hydralazine Hcl | 217 | 32 |
| Memantine Hcl | Memantine Hcl | 206 | 33 |
| Myrbetriq | Mirabegron | 202 | 17 |
| Allopurinol | Allopurinol | 201 | 46 |
| Carvedilol | Carvedilol | 197 | 32 |
| Prednisone | Prednisone | 187 | 38 |
| Latanoprost | Latanoprost | 184 | 32 |
| Quetiapine Fumarate | Quetiapine Fumarate | 182 | 40 |
| Torsemide | Torsemide | 170 | 32 |
| Jardiance | Empagliflozin | 165 | 26 |
| Risperidone | Risperidone | 161 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 155 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 148 | 37 |
| Midodrine Hcl | Midodrine Hcl | 142 | 23 |
| Januvia | Sitagliptin Phosphate | 135 | 23 |
| Finasteride | Finasteride | 133 | 29 |
| Xarelto | Rivaroxaban | 127 | 18 |
| Buspirone Hcl | Buspirone Hcl | 125 | 39 |
| Olanzapine | Olanzapine | 119 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 117 | 18 |
| Enulose | Lactulose | 115 | 14 |
| Ezetimibe | Ezetimibe | 115 | 26 |
| Ondansetron Hcl | Ondansetron Hcl | 110 | 57 |
| Alendronate Sodium | Alendronate Sodium | 107 | 23 |
| Metformin Hcl Er | Metformin Hcl | 105 | 21 |
| Amiodarone Hcl | Amiodarone Hcl | 104 | 16 |
| Farxiga | Dapagliflozin Propanediol | 98 | 18 |
| Valsartan | Valsartan | 98 | 24 |
| Levetiracetam | Levetiracetam | 95 | 14 |
| Levofloxacin | Levofloxacin | 95 | 59 |
| Folic Acid | Folic Acid | 92 | 22 |
| Clonazepam | Clonazepam | 91 | 17 |
| Nifedipine Er | Nifedipine | 91 | 11 |
| Baclofen | Baclofen | 89 | 27 |
| Methenamine Hippurate | Methenamine Hippurate | 85 | 12 |
| Montelukast Sodium | Montelukast Sodium | 85 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 84 | 37 |
| Azithromycin | Azithromycin | 84 | 58 |
| Tramadol Hcl | Tramadol Hcl | 84 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 81 | 16 |
| Nystatin | Nystatin | 78 | 31 |
| Atenolol | Atenolol | 77 | 19 |
| Bupropion Xl | Bupropion Hcl | 77 | 15 |
| Ceftriaxone | Ceftriaxone Sodium | 76 | 28 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 70 | 11 |
| Alprazolam | Alprazolam | 67 | 26 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 66 | suppressed |
| Entresto | Sacubitril/Valsartan | 65 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 62 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 61 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 61 | 14 |
| Spironolactone | Spironolactone | 59 | 18 |
| Glimepiride | Glimepiride | 57 | 12 |
| Lorazepam | Lorazepam | 56 | 18 |
| Protonix | Pantoprazole Sodium | 56 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | 12 |
| Telmisartan | Telmisartan | 55 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 54 | 27 |
| Vascepa | Icosapent Ethyl | 54 | suppressed |
| Budesonide | Budesonide | 53 | suppressed |
| Clozapine | Clozapine | 53 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | suppressed |
| Cephalexin | Cephalexin | 52 | 35 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 52 | 38 |
| Warfarin Sodium | Warfarin Sodium | 52 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 51 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 51 | 28 |
| Lurasidone Hcl | Lurasidone Hcl | 48 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 48 | suppressed |
| Lactulose | Lactulose | 47 | 11 |
| Trulicity | Dulaglutide | 47 | 13 |
| Liothyronine Sodium | Liothyronine Sodium | 46 | 11 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 46 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 42 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 42 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | 11 |
| Hydrocortisone | Hydrocortisone | 40 | 11 |
| Lokelma | Sodium Zirconium Cyclosilicate | 40 | 15 |
| Oxcarbazepine | Oxcarbazepine | 40 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 33 |
| Labetalol Hcl | Labetalol Hcl | 38 | suppressed |
| Linzess | Linaclotide | 38 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 37 | suppressed |
| Digoxin | Digoxin | 37 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 36 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 36 | suppressed |
| Amoxicillin | Amoxicillin | 35 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 35 | 14 |
| Methylprednisolone | Methylprednisolone | 35 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 34 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 34 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 33 | 27 |
| Sevelamer Carbonate | Sevelamer Carbonate | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 19 |
| Memantine Hcl Er | Memantine Hcl | 32 | suppressed |
| Ramipril | Ramipril | 32 | 11 |
| Tradjenta | Linagliptin | 31 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 30 | suppressed |
| Brilinta | Ticagrelor | 30 | suppressed |
| Rexulti | Brexpiprazole | 30 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 29 | 15 |
| Cefuroxime | Cefuroxime Axetil | 29 | 21 |
| Cholestyramine | Cholestyramine (With Sugar) | 29 | suppressed |
| Mupirocin | Mupirocin | 29 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 29 | 28 |
| Rivastigmine | Rivastigmine | 29 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Nyamyc | Nystatin | 28 | 15 |
| Restasis | Cyclosporine | 28 | suppressed |
| Irbesartan | Irbesartan | 27 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 26 | suppressed |
| Meloxicam | Meloxicam | 26 | 12 |
| Sucralfate | Sucralfate | 26 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 25 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 25 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Anastrozole | Anastrozole | 23 | suppressed |
| Gemtesa | Vibegron | 23 | suppressed |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 23 | 22 |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 22 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 22 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 22 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 22 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 22 | 11 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 21 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 21 | suppressed |
| Dextrose 5%-0.45% Nacl | Dextrose 5 %-0.45 % Sod Chlord | 20 | 14 |
| Formoterol Fumarate | Formoterol Fumarate | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 20 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 19 | suppressed |
| Cyclosporine | Cyclosporine | 19 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 18 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 18 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Clonidine | Clonidine | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 16 |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Fluphenazine Decanoate | Fluphenazine Decanoate | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Secuado | Asenapine | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 12 |
| Thiothixene | Thiothixene | 15 | suppressed |
| Timolol Maleate | Timolol Maleate | 15 | suppressed |
| Admelog Solostar | Insulin Lispro | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 14 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 14 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 14 | 11 |
| Ssd | Silver Sulfadiazine | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Abilify Maintena | Aripiprazole | 13 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Dalfampridine Er | Dalfampridine | 13 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 13 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 13 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Procrit | Epoetin Alfa | 13 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 13 | suppressed |
| Zypitamag | Pitavastatin Magnesium | 13 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 12 | suppressed |
| Budesonide Er | Budesonide | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Dextrose In Water | Dextrose 5 % In Water | 12 | 11 |
| Glipizide | Glipizide | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 12 | 12 |
| Lamotrigine Er | Lamotrigine | 12 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Silodosin | Silodosin | 12 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 12 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Levoxyl | Levothyroxine Sodium | 11 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Lumigan | Bimatoprost | 11 | suppressed |
| Mesalamine Er | Mesalamine | 11 | suppressed |
| Sodium Chloride | Sodium Chloride 0.45 % | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $963.98 · 50 records | Lilly USA, LLC | Arikayce, Brinsupri, EVENITY, FARXIGA, FUROSCIX, GEMTESA, INGREZZA, JARDIANCE, KISUNLA, Kerendia, LEQVIO, Leqembi, MOUNJARO, Ozempic, REXULTI, Rybelsus, TRELEGY ELLIPTA, TZIELD | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error